140 related articles for article (PubMed ID: 38736011)
21. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
22. Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Griebling TL
J Urol; 2015 Mar; 193(3):947. PubMed ID: 25765412
[No Abstract] [Full Text] [Related]
23. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
Mullen GR; Kaplan SA
Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
[TBL] [Abstract][Full Text] [Related]
24. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
[TBL] [Abstract][Full Text] [Related]
25. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
Kasjan GR
Urologiia; 2015; (4):121-4. PubMed ID: 26665779
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
Kinjo M; Masuda K; Nakamura Y; Miyakawa J; Tambo M; Fukuhara H
Urology; 2023 May; 175():67-73. PubMed ID: 36822245
[TBL] [Abstract][Full Text] [Related]
27. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
Cruz F
Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
[No Abstract] [Full Text] [Related]
28. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.
Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N
Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579
[TBL] [Abstract][Full Text] [Related]
29. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
[TBL] [Abstract][Full Text] [Related]
30. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
31. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
32. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
Zachariou A; Mamoulakis C; Filiponi M; Dimitriadis F; Giannakis J; Skouros S; Tsounapi P; Takenaka A; Sofikitis N
BMC Urol; 2018 Jun; 18(1):61. PubMed ID: 29940933
[TBL] [Abstract][Full Text] [Related]
33. Combination of solifenacin and mirabegron for overactive bladder management.
Cornu JN
BJU Int; 2015 Oct; 116(4):498-9. PubMed ID: 26350574
[No Abstract] [Full Text] [Related]
34. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
Iitsuka H; van Gelderen M; Katashima M; Takusagawa S; Sawamoto T
Clin Ther; 2015 May; 37(5):1031-44. PubMed ID: 25791612
[TBL] [Abstract][Full Text] [Related]
35. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Sharaf A; Hashim H
Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
[TBL] [Abstract][Full Text] [Related]
37. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
39. Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.
Makhani A; Thake M; Gibson W
Clin Interv Aging; 2020; 15():575-581. PubMed ID: 32368024
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
